Education
About Us
Working with TipRanks
Follow Us
Shanghai Pharmaceuticals Holding Co Class H (HK:2607)
:2607
Total Valuation
Shanghai Pharmaceuticals Holding Co has a market cap or net worth of HK$75.85B. The enterprise value is HK$81.26B.
Market CapHK$75.85B
Enterprise ValueHK$81.26B
Share Statistics
Shanghai Pharmaceuticals Holding Co has 919,072,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding919,072,700
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Shanghai Pharmaceuticals Holding Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.47%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.47%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee5.57M
Profits Per Employee118.82K
Employee Count49,402
Asset Turnover1.24
Inventory Turnover6.28
Valuation Ratios
The current PE Ratio of Shanghai Pharmaceuticals Holding Co is 6.8. Shanghai Pharmaceuticals Holding Co’s PEG ratio is 0.47.
PE Ratio6.8
PS Ratio0.16
PB Ratio0.61
Price to Fair Value0.61
Price to FCF12.82
Price to Operating Cash Flow9.59
PEG Ratio0.47
Income Statement
In the last 12 months, Shanghai Pharmaceuticals Holding Co had revenue of 275.25B and earned 4.55B in profits. Earnings per share was 1.23.
Revenue275.25B
Gross Profit30.63B
Operating Income8.14B
Pretax Income8.02B
Net Income4.55B
EBITDA12.06B
Earnings Per Share (EPS)1.23
Cash Flow
In the last 12 months, operating cash flow was 989.26M and capital expenditures -1.12B, giving a free cash flow of 2.34B billion.
Operating Cash Flow989.26M
Free Cash Flow2.34B
Free Cash Flow per Share2.55
Dividends & Yields
Shanghai Pharmaceuticals Holding Co pays an annual dividend of HK$0.317, resulting in a dividend yield of 2.64%
Dividend Per ShareHK$0.317
Dividend Yield2.64%
Payout Ratio35.50%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change-2.77%
50-Day Moving Average12.44
200-Day Moving Average11.79
Relative Strength Index (RSI)39.59
Average Volume (3m)3.78M
Important Dates
Shanghai Pharmaceuticals Holding Co upcoming earnings date is Oct 24, 2025, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateOct 24, 2025
Ex-Dividend DateJul 16, 2025
Financial Position
Shanghai Pharmaceuticals Holding Co as a current ratio of 1.36, with Debt / Equity ratio of 68.88%
Current Ratio1.36
Quick Ratio1.05
Debt to Market Cap1.06
Net Debt to EBITDA1.00
Interest Coverage Ratio5.01
Taxes
In the past 12 months, Shanghai Pharmaceuticals Holding Co has paid 2.15B in taxes.
Income Tax2.15B
Effective Tax Rate0.27
Enterprise Valuation
Shanghai Pharmaceuticals Holding Co EV to EBITDA ratio is 4.64, with an EV/FCF ratio of 16.33.
EV to Sales0.20
EV to EBITDA4.64
EV to Free Cash Flow16.33
EV to Operating Cash Flow9.60
Balance Sheet
Shanghai Pharmaceuticals Holding Co has HK$47.50B in cash and marketable securities with HK$51.73B in debt, giving a net cash position of -HK$4.23B billion.
Cash & Marketable SecuritiesHK$47.50B
Total DebtHK$51.73B
Net Cash-HK$4.23B
Net Cash Per Share-HK$4.60
Tangible Book Value Per ShareHK$18.02
Margins
Gross margin is 10.55%, with operating margin of 2.96%, and net profit margin of 1.65%.
Gross Margin10.55%
Operating Margin2.96%
Pretax Margin2.91%
Net Profit Margin1.65%
EBITDA Margin4.38%
EBIT Margin3.50%
Analyst Forecast
The average price target for Shanghai Pharmaceuticals Holding Co is HK$13.54, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$13.54
Price Target Upside12.70% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast3.60%
EPS Growth Forecast47.33%